Join
Live feed
·
NEWSReleasevia Quantisnow
Aptevo Therapeutics Inc. logo

Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025

ByQuantisnow·Wall Street's wire, on your screen.
APVO· Aptevo Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track APVO (Aptevo Therapeutics Inc.) and more on Quantisnow.